A Highly Efficient Synthesis of a Naphthalenoid Histamine-3 Antagonist
FULL PAPERS
temperature below À158C (this took about 30 min). After
addition, the resulting mixture was stirred at À158C for
10 min and quenched with H2O (5 mL) and allowed to
warm to room temperature. The organic solution was fil-
tered through a pad of Celite to remove some solid. The fil-
trate was concentrated to about 30 mL volume, EtOAc
(200 mL) was added followed by 5% NaHCO3 (150 mL).
The organic layer was separated, washed with 5% NaHCO3
(2ꢁ150 mL), and extracted with 2N HCl (3ꢁ150 mL). The
HCl salt of the desired product slowly precipitated out from
the aqueous solution upon addition of brine (150 mL). The
resulting suspension was cooled to 08C, stirred at 08C for 1
hour and filtered. The product was dried in a vacuum oven
at 508C for 24 hour to obtain the product as an HCl salt;
yield: 18.1 g (the product was analyzed against pure refer-
ence standard and determined to have a 87% w/w potency,
resulting in a 65% potency adjusted isolated yield).
The crude product is used in the next step without further
purification. A small pure reference sample was obtained by
recrytallization to obtain the pure product as a solid. The
NMR spectra were taken using the free base obtained from
the purified HCl salt. 1H NMR (CDCl3): d=7.95 (d, J=
1.8 Hz, 1H), 7.63–7.68 (m, 3H), 7.49–7.51 (dd, J=8.6,
1.9 Hz, 1H), 7.36–7.38 (dd, J=8.3, 1.8 Hz, 1H), 3.36–3.41
(m, 1H), 3.16–3.23 (m, 1H), 3.01–3.07 (m, 2H), 2.47–2.58
(m, 2H), 2.40 (m, 1H), 1.98–2.05 (m, 1H), 1.87–1.93 (m,
1H), 1.76–1.82 (m, 1H), 1.52–1.61 (m, 1H), 1.21 (d, J=
6.2 Hz, 3H); 13C NMR (CDCl3): d=137.69, 132.86, 131.66,
129.34, 129.04, 128.82, 128.10, 126.84, 126.54, 118.93, 60.78,
55.37, 53.62, 34.80, 32.58, 21.88, 18.24; APCI-MS: m/z=319
(M+H)+; anal. calcd. for C17H21BrClN: C 57.56, H 5.97, N,
3.95; found: C 57.54, H 5.98, N 3.91.
lution was charged into the mixture until the pH of the mix-
ture is ~13. The upper organic phase was separated, and the
lower aqueous solution was extracted once with isopropyl
acetate (50 mL). The combined organic solution was washed
with 5% NaHCO3 (250 mL x2), and 25% brine (200 mL),
dried over Na2SO4, and filtered. The filtrate was concentrat-
ed to dryness, and ethyl acetate (170 mL) was added. The
resulting solution was heated to 408C, and salicylic acid
(4.80 g, 34.7 mmol) was added. The solution was stirred at
408C for 2 h, and cooled to 208C. The slurry was mixed for
2 h, filtered, washed with ethyl acetate (50 mL), dried under
vacuum at 558C overnight to afford 12.7 g of the salicylate.
This salt was then freed up in a mixture ethyl acetate
(150 mL) and 10% Na2CO3 aqueous solution (100 mL). The
organic solution was washed with 20% brine (150 mLꢁ2),
dried over Na2SO4, filtered. The filtrate was concentrated to
dryness, and azeotroped with absolute ethanol (100 mL) to
dryness. The residue was dissolved in absolute ethanol
(200 mL), and the solution was heated to 408C. Anhydrous
citric acid (18.1 g, 94.3 mmol) was added all at once, and the
solution seeded with small amount of bis-citrate salt. The so-
lution was mixed at 408C for 5 h, and the slurry was cooled
to 258C, and mixed for 2 h. The product was isolated by fil-
tration, washed with absolute ethanol (100 mL), dried under
vacuum at 508C overnight to give the bis-citrate salt as an
off-white solid; yield: 18.4 g (70% overall); mp 150–1528C.
1HNMR (DMSO-d6): d=8.12 (d, J=1.7 Hz, 1H), 8.10 (dd,
J=3.8, 1.5 Hz), 7.98 (d, J=8.4 Hz, 1H), 7.96 (d, J=8.9 Hz,
1H), 7.90 (s, 1H), 7.68 (dd, J=8.6, 2.1 Hz, 1H), 7.55 (dd,
J=8.4, 1.4 Hz, 1H), 7.52 (dd, J=9.6, 3.8 Hz, 1H), 7.11 (dd,
J=9.5, 1.6 Hz, 1H), 3.60 (m, 2H), 3.47 (m, 1H), 3.21 (m,
4H), 2.67 (d, J=15.3 Hz, 4H), 2.58 (d, J=15.3 Hz, 4H),
2.18 (m, 1H), 1.95 (m, 2H), 1.62 (m, 1H), 1.35 (d, J=
6.5 Hz, 3H); 13C NMR (DMSO-d6): d=175.89, 171.36,
159.50, 138.90, 137.68, 135.80, 132.51, 132.12, 131.53, 130.71,
128.51, 128.02, 127.75, 126.91, 124.17, 123.85, 71.91, 63.16,
52.58, 43.59, 31.31, 30.90, 21.08, 15.58; APCI-MS (ESI):
m/z=334 (M+1); anal. calcd. for C33H39N3O15: C 55.23, H
5.48, N 5.86; found: C 55.26, H 5.31, N 5.87; Pd=8 ppm,
Cu=3 ppm.
2-{6-[2-(Methyl-1-pyrrolidin-1-yl)-ethyl]-2-
naphthalen-2-yl}-2H-pyridazin-3-one (1A)[3c]
To a reaction vessel were charged 1-[2-(6-bromonaphthalen-
2-yl)-ethyl]-2(R)-methylpyrrolidine
(12.5 g, 87 w/w% potency, 36.8 mmol), CuCl (174 mg,
1.75 mmol, 5 mol%), 8-hydroxyquinoline (514 mg,
hydrochloride
(10)
3.54 mmol, 10 mol%), K2CO3 powder (12.19 g, 88.0 mmol),
2H-pyridazin-3-one (4) (5.06 g, 52.7 mmol), and DMF
(57 mL). The reaction vessel was evacuated, and backfilled References
with N2 (repeated 3 times). The reaction vessel was then
pressurized with N2 to 5 psi, and the mixture was heated to
1408C, and maintained for 18 h (HPLC indicated complete
consumption of the starting material) (Caution: the internal
pressure will rise, and must be vented as needed). The reac-
tion mixture was cooled to 208C, and isopropyl acetate
(200 mL), 30% NH4OH (100 mL), 4% Na2EDTA-23%
NaCl solution (100 mL) were added. The mixture was agi-
tated for 0.5 h, filtered through a pad of filter aid, rinsed
with isopropyl acetate (20 mL). The lower aqueous solution
was extracted with isopropyl acetate (50 mL). The combined
organic layers were washed with 4% Na2EDTA-23%NaCl
solution (250 mLꢁ3) and analyzed against reference stan-
dard to contain 9.80 g of the free base of 1 (84% assayed
yield). It was then concentrated to ~200 mL volume and ex-
tracted with a mixture of H2O:CH3SO3H:NMP (70:10:20 by
volume) (150 mL followed by 50 mL). Isopropyl acetate
(200 mL) was added to the combined aqueous extract, and
the mixture was cooled to <108C. 50% NaOH aqueous so-
[1] a) For reviews, see: R. Leurs, P. Blandina, C. Tedford,
H. Timmerman, Trends Pharmacol. Sci. 1998, 19, 177;
b) The Histamine H3 Receptor: A Target for New
Drugs, (Eds.: R. Leurs, H. Timmerman), Pharmaco-
chemistry Library, vol. 30, Elsevier: Amsterdam, Neth-
erlands, 1998.
[2] a) G. B. Fox, J. B. Pan, R. J. Radek, A. M. Lewis, R. S.
Bitner, T. A. Esbenshade, R. Faghih, Y. L. Bennani, M.
Williams, B. B. Yao, M. W. Decker, A. A. Hancock, J.
Pharmacol. Exp. Ther. 2003, 305, 897; b) C. Bjenning,
W. Liu, K. Rimvall, International Congress Series, 2001,
1224 (Histamine Research in the New Millennium),
pp 451–452.
[3] a) M. Cowart, J. K. Pratt, A. O. Stewart, Y. L. Bennani,
T. A. Esbenshade, A. A. Hancock, Bioorg. Med. Chem.
Lett. 2004, 14, 689; b) R. J. Altenbach, L. A. Black, S-J.
Chang, M. D. Cowart, R. Faghih, G. A. Gfesser, Y. Y.
Ku, H. Liu, K. A. Lukin, D. L. Nersesian, Y. M. Pu,
Adv. Synth. Catal. 2009, 351, 2024 – 2030
ꢀ 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2029